Skip to main content
Premium Trial:

Request an Annual Quote

3D Signatures Sells 2M Shares to ScreenCell for C$500K

NEW YORK (GenomeWeb) – Personalized medicine company 3D Signatures announced late yesterday that it has sold 2 million shares of its common stock in a private placement to French biotechnology company ScreenCell for gross proceeds of C$500,000 (US$400,198).

3DS is developing diagnostic and prognostic tests based on a proprietary platform that analyzes the spatial patterns of chromosomes by tagging and imaging their telomeres. The proceeds from the placement, under which the stock was sold for C$.25 per share, will be used primarily to fund 3DS' clinical operations, namely its Hodgkin's lymphoma test clinical trial, including clinical wages and laboratory expenses. The rest will be used for general working capital.

ScreenCell has been working with 3DS since the company was founded and supplies it with a screening system for the capture and isolation of circulating tumor cells from blood.

"It's a strong endorsement of 3DS when a major supplier and technology collaborator makes a financial investment in the company," 3DS CEO Jason Flowerday said in a statement. "ScreenCell is a leader in its field and we look forward to a continued partnership."

In July, the company filed paperwork with Canadian regulators to privately sell up to 12.5 million shares of its common stock in the US for a total of C$5 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more